ROME -- Findings from two small studies of the investigational drug, tranilast, suggest that the drug is well tolerated and effective for lowering serum uric acid.
Measurable and significant differences in serum uric acid and in uric acid secretion were observable as soon as four hours after the experimental uricosuric, tranilast, was orally administered to subjects in the study, said John Sundy, MD, of the Duke Clinical Research Institute.
Sundy reported results from two small trials of healthy volunteers in a poster at the European League Against Rheumatism meeting here.
"These are very early studies in the clinical development, but these appear to be promising findings," he said.
"The results we observed in these trials support clinical studies of tranilast as urate lowering therapy for the chronic management of hyperuricemia in patients with gout," Sundy told MedPage Today.
Tranilast, a compound that stabilizes mast cells, is available in Japan for treatment of pulmonary and dermatologic conditions, and has been observed to have analgesic anti-inflammatory properties, Sundy explained.
http://www.medpagetoday.com/Rheumatology/GeneralRheumatology/20843Bumping to push down the spam!Good info!bumpingUp, up and away!In my beautiful ballooncareful now...you could be posting too much in a certain time frame...LOLMeasurable and significant differences in serum uric acid and in uric acid secretion were observable as soon as four hours after the experimental uricosuric, tranilast, was orally administered to subjects in the study, said John Sundy, MD, of the Duke Clinical Research Institute.
Sundy reported results from two small trials of healthy volunteers in a poster at the European League Against Rheumatism meeting here.
"These are very early studies in the clinical development, but these appear to be promising findings," he said.
"The results we observed in these trials support clinical studies of tranilast as urate lowering therapy for the chronic management of hyperuricemia in patients with gout," Sundy told MedPage Today.
Tranilast, a compound that stabilizes mast cells, is available in Japan for treatment of pulmonary and dermatologic conditions, and has been observed to have analgesic anti-inflammatory properties, Sundy explained.
http://www.medpagetoday.com/Rheumatology/GeneralRheumatology/20843ROME -- Findings from two small studies of the investigational drug, tranilast, suggest that the drug is well tolerated and effective for lowering serum uric acid.Measurable and significant differences in serum uric acid and in uric acid secretion were observable as soon as four hours after the experimental uricosuric, tranilast, was orally administered to subjects in the study, said John Sundy, MD, of the Duke Clinical Research Institute.
Sundy reported results from two small trials of healthy volunteers in a poster at the European League Against Rheumatism meeting here.
"These are very early studies in the clinical development, but these appear to be promising findings," he said.
"The results we observed in these trials support clinical studies of tranilast as urate lowering therapy for the chronic management of hyperuricemia in patients with gout," Sundy told MedPage Today.
Tranilast, a compound that stabilizes mast cells, is available in Japan for treatment of pulmonary and dermatologic conditions, and has been observed to have analgesic anti-inflammatory properties, Sundy explained.
http://www.medpagetoday.com/Rheumatology/GeneralRheumatology/20843 ROME -- Findings from two small studies of the investigational drug, tranilast, suggest that the drug is well tolerated and effective for lowering serum uric acid.Measurable and significant differences in serum uric acid and in uric acid secretion were observable as soon as four hours after the experimental uricosuric, tranilast, was orally administered to subjects in the study, said John Sundy, MD, of the Duke Clinical Research Institute.
Sundy reported results from two small trials of healthy volunteers in a poster at the European League Against Rheumatism meeting here.
"These are very early studies in the clinical development, but these appear to be promising findings," he said.
"The results we observed in these trials support clinical studies of tranilast as urate lowering therapy for the chronic management of hyperuricemia in patients with gout," Sundy told MedPage Today.
Tranilast, a compound that stabilizes mast cells, is available in Japan for treatment of pulmonary and dermatologic conditions, and has been observed to have analgesic anti-inflammatory properties, Sundy explained.
http://www.medpagetoday.com/Rheumatology/GeneralRheumatology/20843 ROME -- Findings from two small studies of the investigational drug, tranilast, suggest that the drug is well tolerated and effective for lowering serum uric acid.Measurable and significant differences in serum uric acid and in uric acid secretion were observable as soon as four hours after the experimental uricosuric, tranilast, was orally administered to subjects in the study, said John Sundy, MD, of the Duke Clinical Research Institute.
Sundy reported results from two small trials of healthy volunteers in a poster at the European League Against Rheumatism meeting here.
"These are very early studies in the clinical development, but these appear to be promising findings," he said.
"The results we observed in these trials support clinical studies of tranilast as urate lowering therapy for the chronic management of hyperuricemia in patients with gout," Sundy told MedPage Today.
Tranilast, a compound that stabilizes mast cells, is available in Japan for treatment of pulmonary and dermatologic conditions, and has been observed to have analgesic anti-inflammatory properties, Sundy explained.
http://www.medpagetoday.com/Rheumatology/GeneralRheumatology/20843 OH GREAT YET ANOTHER NEW DRUG. MAYBE THIS TIME IT WILL REALLY WORK FOR ME SINCE I AM STILL DRINKING AND EATING TONS OF GARBAGE MAYBE THIS ONE WILL JUST FIX ME RIGHT UP.ROME -- Findings from two small studies of the investigational drug, tranilast, suggest that the drug is well tolerated and effective for lowering serum uric acid.Measurable and significant differences in serum uric acid and in uric acid secretion were observable as soon as four hours after the experimental uricosuric, tranilast, was orally administered to subjects in the study, said John Sundy, MD, of the Duke Clinical Research Institute.
Sundy reported results from two small trials of healthy volunteers in a poster at the European League Against Rheumatism meeting here.
"These are very early studies in the clinical development, but these appear to be promising findings," he said.
"The results we observed in these trials support clinical studies of tranilast as urate lowering therapy for the chronic management of hyperuricemia in patients with gout," Sundy told MedPage Today.
Tranilast, a compound that stabilizes mast cells, is available in Japan for treatment of pulmonary and dermatologic conditions, and has been observed to have analgesic anti-inflammatory properties, Sundy explained.
http://www.medpagetoday.com/Rheumatology/GeneralRheumatology/20843